Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Clinical trial NCT04639245 · TERMINATED

Trial details

NCT number: NCT04639245
Sponsor: Fred Hutchinson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Triple-Negative Breast Carcinoma Metastatic Urothelial Carcinoma Stage IV Lung Cancer AJCC v8

Start date: 2021-07-19
Primary completion: 2022-08-04
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.